G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin’s lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin’s lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
Authors
Keywords
Granulocyte-colonystimulating factor, Febrile neutropenia, Chemotherapy, Non-Hodgkin’s lymphoma, Observational study, Clinical practice
Journal
MEDICAL ONCOLOGY
Volume 33, Issue 12, Pages -
Publisher
Springer Nature
Online
2016-11-07
DOI
10.1007/s12032-016-0850-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
- (2017) Gary H. Lyman Journal of the National Comprehensive Cancer Network
- Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor
- (2015) Tara Arvedson et al. BIODRUGS
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Thomas J. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
- (2015) Li Wang et al. SUPPORTIVE CARE IN CANCER
- Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis
- (2014) Derek Weycker et al. BMC HEALTH SERVICES RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia
- (2014) Sol Cortés de Miguel et al. SUPPORTIVE CARE IN CANCER
- Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
- (2014) Alena M. Pfeil et al. SUPPORTIVE CARE IN CANCER
- The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
- (2013) G. H. Lyman et al. ANNALS OF ONCOLOGY
- A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
- (2013) S. Barni et al. MEDICAL ONCOLOGY
- A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia
- (2013) Brian Dulisse et al. JOURNAL OF MEDICAL ECONOMICS
- ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
- (2012) M. Ghielmini et al. ANNALS OF ONCOLOGY
- Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Regimens
- (2012) Pieternella Lugtenburg et al. Clinical Lymphoma Myeloma & Leukemia
- Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice
- (2012) Hans E. Johnsen et al. LEUKEMIA & LYMPHOMA
- The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice
- (2012) Antonio Salar et al. LEUKEMIA RESEARCH
- Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
- (2011) Ruth Pettengell et al. SUPPORTIVE CARE IN CANCER
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
- (2010) J. Crawford et al. ANNALS OF ONCOLOGY
- How I treat elderly patients with diffuse large B-cell lymphoma
- (2010) M. Pfreundschuh BLOOD
- Risk of mortality in patients with cancer who experience febrile neutropenia
- (2010) Gary H. Lyman et al. CANCER
- Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
- (2010) Hans Wildiers et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial
- (2009) S. Luminari et al. ANNALS OF ONCOLOGY
- Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
- (2008) R. Pettengell et al. ANNALS OF HEMATOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
- (2008) Ruth Pettengell et al. SUPPORTIVE CARE IN CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search